Endocrine Abstracts

CAH has been described to be associated to infertility and semen abnormalities in 40–70% of adult male patients, because of hypogonodotropic hypogonadism, consequent to the increased levels of sex steroids, but mostly because of the frequent presence of testicular adrenal rest tumors. The aim of the current study was to evaluate semen parameters and hormonal setting in a subset of men with CAH. Fourteen patients with classical CAH due to 21-HD (six with simple virilizing,...

Introduction: Bone metabolism is impaired in several lipid storage diseases. At now no data are available in Fabry disease (FD), a genetic lipid storage disease characterized by systemic accumulation of glicolipids. The aim of this study was to evaluate bone metabolism and calcium/vitamin-D pathway in patients with FD.Methods/design: Study population included 15 FD patients (8 M and 7 F, age 28–59 years) and 15 sex-, age- and BMI-matched normal subj...

Introduction: Acromegaly is a systemic disease frequently characterized by hypogonadotropic hypogonadism, endothelial dysfunction and diseases classically associated with an increased incidence of erectile dysfunction (ED) (hypertension, dyslipidemia, impaired glucose metabolism) and premature ejaculation (prostatic disease). Furthermore, the high prevalence of ED may negatively affect ejaculatory function. The purpose of this study was to evaluate the ejaculatory function of ...

Introduction: Acromegaly is frequently characterized by hypogonadotropic hypogonadism, endothelial dysfunction, hypertension and impaired glucose and lipid metabolism, classically associated with impaired sexual function (SF). There are no literature data on the SF in acromegaly. The purpose of this study was to evaluate the SF of patients with acromegaly.Patients and methods: Twenty-two patients (47.8±8.6 years) were enrolled into the study. Among ...

Introduction: Rapid and sustained decreases in UFC and significant improvements in signs and symptoms were seen in a large, randomized, 12-month phase III study of pasireotide in Cushing’s disease. The safety profile of pasireotide was found to be similar to that of other somatostatin analogues, with the exception of hyperglycemia-related AEs (reported in 72.8% of patients). This abstract reports safety data from a 12-month extension to this phase III trial.<p class="...

Introduction: The large, randomized, phase III study of pasireotide in Cushing’s disease found that pasireotide treatment resulted in rapid and sustained decreases in UFC levels and in significant improvements in signs and symptoms over 12 months of treatment. A 12-month extension of this trial has recently completed, and the results are reported here.Methods: Patients with persistent/recurrent or de novo (if not surgical candidates) Cushing&...

Cushing’s syndrome (CS) is a severe disease caused by an endogenous glucocorticoid excess and it is correlated to an increased morbidity and mortality especially for sepsis and cardiovascular diseases, while hypertension, glucose intolerance or diabetes mellitus, and dyslipidemia are the most common systemic complications. The aim of this retrospective study was to evaluate the mortality and morbidity of patients with CS admitted at the Department of Endocrinology and Onc...

Cabergoline (CAB) was demonstrated to be effective in normalizing cortisol secretion in a subset of patients with Cushing’s disease (CD). The aim of the study was to evaluate the impact of chronic treatment with CAB on clinical, metabolic and hormonal parameters in CD patients. Twenty-six patients with CD (11 males, 15 females, 12–72 years) entered the study. Patients were divided into two groups, responders and non responders, according to the achievement or not of ...

Women with acromegaly present often menstrual irregularity, anovularity and infertility. A direct role of GH and IGF1 excess on the hypothalamus–pituitary–gonadal axis, hyperprolactinemia and an impaired gonadotrophin secretion related to a tumor mass effect, or polycystic ovary syndrome have been suggested as possible mechanisms related to infertility. However, no systematic data are available on fertility in these patients. The aim of this retrospective study was t...

The dopamine agonist cabergoline has been found to be effective in inducing normalization of cortisol secretion in 25–50% of patients with Cushing’s disease after long-term treatment. Moreover, tumor shrinkage have been documented in selected patients with pituitary corticotroph tumors. The aim of the present study was to evaluate the effect of cabergoline withdrawal in patients with a stable normalization of cortisol secretion and stable or absent visualization of p...